Molax/Molax-M Drug Interactions

Antacids and antisecretory drugs: These drugs lower the oral availability of MOLAX SUSPENSION.
Opioid analgesics and antimuscarinics: The prokinetic effects of Domperidone may be antagonized by such drugs.
Potent CYP3A4 inhibitors: These drugs may increase the plasma concentration of Domperidone. Potent CYP3A4 includes Azole antifungals e.g., fluconazole, itraconazole, ketoconazole, voriconazole; macrolide antibiotics e.g., clarithromycin and erythromycin, HIV protease inhibitors e.g., amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir and saquinavir; calcium antagonists e.g., diltiazem and verapamil; amiodarone, aprepitant, nefazodone, telithromycin.
Some potent CYP3A4 inhibitors: Fluconazole, ketoconazole, voriconazole, clarithromycin, erythromycin, amiodarone, telithromycin; produce an associated slight prolongation in QT interval. Concomitant use with Domperidone is not recommended.
Dopaminergic agonists: Domperidone may antagonize the hypoprolactinaemia effect of bromocriptine. It also may suppress the unwanted peripheral effect of bromocriptine and L-dopa e.g., digestive disorders, nausea and vomiting, without counteracting their central properties.
Sustained-release and enteric-coated formulations of drugs: Domperidone enhances gastric and small intestinal motive, it may accelerate absorption of drugs from the small bowel with slowing absorption of drugs taken up from stomach, particularly those with sustained-release or enteric-coated formulations.